VEGF superagonist (human)

VEGF superagonist (human) is a recombinant protein analog developed by Trophogen that acts as a high-potency agonist of the vascular endothelial growth factor (VEGF) receptor. While VEGF signaling is typically targeted for inhibition in oncology to suppress angiogenesis, Trophogen's superagonist analogs are engineered to intensely activate these receptors. According to company pipeline information, the drug is in preclinical development for the treatment of thyroid cancer and other malignancies. The therapeutic rationale may involve modulating the tumor microenvironment or enhancing the delivery and uptake of co-administered treatments, leveraging Trophogen's proprietary technology for creating long-acting, high-affinity glycoprotein and growth factor analogs.

Other names

human VEGF superagonistVEGF superagonist analoghuman VEGF superagonist analogs